The present disclosure provides genetically engineered microorganisms for tagatose production comprising one or more heterologous polynucleotides encoding polypeptides selected from cellodextrin transporter (Cdt-1), intracellular β-glucosidase (Gh1-1), xylose reductase (XR), galactitol 2-dehydrogenase (Gdh) and an AraA polypeptide, wherein any biological activity of endogenous Gal1 is attenuated or eliminated. Also provided are genetically engineered microorganism for psicose production comprising one or more heterologous polynucleotides encoding polypeptides selected from alpha-glucoside permease (Agt1) and psicose epimerase (Dpe), wherein any biological activity of endogenous sucrose invertase (Suc2), hexose kinase 1 (Hxk1), hexose kinase 2 (Hxk2), or combinations thereof are attenuated or eliminated. Methods of converting lactose to tagatose and sucrose to psicose is also provided.
|Original language||English (US)|
|U.S. patent number||10570467|
|State||Published - Feb 25 2020|